Key changes include sections guiding education and marketing programs, communication on safe and effective use of medtech, and on providing technical support. The update also expands provisions on support for third-party educational and other conferences.
News & Features
The magazine published a special January edition on "The Future of Medicine" highlighting innovative organs-on-chips research and technology.
Each year the J.P. Morgan Healthcare Conference serves as the start of medtech’s season. Now that it has ended, here are 7 key things we learned about companies presenting during the event.
The San Clemente, CA-based firm is developing several glaucoma treatment products as it transitions into a hybrid surgical, pharmaceutical, and medical device company.
The first donor-derived cell-free DNA test to assess allograft health in kidney transplant patients is also beneficial for repeat transplant recipients, a new study finds.
A half-day workshop at MD&M West will give attendees the chance to interact with both patients and new technologies. The session can help designers and engineers rapidly understand user needs and how empathy and co-creation can occur even within compressed schedules.
The San Diego-based company presented at the 37th annual J.P. Morgan Healthcare Conference and said its revenue increased by 43% in 2018 despite mounting competition from rivals.
The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.
CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with screenings and increase detection rates.
A team of researchers at the Imperial College London have developed a process known as known as traction force-activated payloads (TrAPs), that could have a significant impact on the body’s natural ability to heal.